UnknownNot Applicable

Immune Response to COVID-19 Vaccine in Recipients of Living Donor Liver Transplantation

Egypt50 participantsStarted 2021-09-15

Plain-language summary

A prospective cohort study to evaluate the response to COVID-19 vaccine in liver transplantation patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age\>18 * At least 3 month post transplantation Exclusion Criteria: * pediatric recipients * Active covid infection at the time of the study * Pregnancy * Allergy to any ingredients included in the vaccine * Lactation in first six month of delivery * Active Acute cellular rejection proven by liver biopsy * Acute Febrile state with either leucopenia or leucocytosis * High dose of corticosteroid at study timing (pulse methyl prednisolone)

What they're measuring

Neutralizing antibody titer change 14 days after vaccination compared to baseline

Timeframe: At baseline, at 14 days after whole course of vaccination

Neutralizing antibody titer change 28 days post vaccination compared to baseline

Timeframe: At baseline and 28 days after whole course of vaccination

Trial details

NCT IDNCT05051605

SponsorAin Shams University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-30

Contact for this trial

Rana Sayed, PhD

01208164247 ranasayed@pharma.asu.edu.eg

View on ClinicalTrials.gov More Liver Transplant trials